Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
New treatments for patients with Waldenstrom's macroglobulinemia (WM) have necessited the development of prognostic indices. Using a sample of 92 patients with refractory or relapsing WM treated in a randomized trial, we show that Morel's prognostic scoring system for patients at diagnosis is also effective in patients with advanced disease.
Lévy
Vincent
V
Morel
Pierre
P
Porcher
Raphaël
R
Chevret
Sylvie
S
Wattel
Eric
E
Leblond
Véronique
V
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D013997:Time Factors; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis* / Q000628:therapy*
D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone